SCHEMBL21880766

SCHEMBL21880766

O=C(O)c1ccc2c(c1)OC(c1ccccc1)N2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.44
▸ KDM4E B2RXH2 3/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ GAA P10253 2/20 0.44
▸ ALOX5 P09917 1/20 0.43
▸ MAPK1 P28482 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.37
▸ PARP1 P09874 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.36
▸ MASP2 O00187 1/20 0.36
▸ HSPA1A P0DMV8 1/20 0.36
▸ CD44 P16070 1/20 0.36
▸ PTPN1 P18031 1/20 0.36
▸ MSN P26038 1/20 0.36
▸ CDC25B P30305 1/20 0.36
▸ AKT1 P31749 1/20 0.36
▸ PTPN7 P35236 1/20 0.36
▸ EZH2 Q15910 1/20 0.36
▸ POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21880385 0.88 ALOX5 (0.50) ALDH1A1KDM4EMEN1KMT2AGAA
SCHEMBL21880533 0.76 MAOB (0.43) MEN1KMT2APOLBMAPT
SCHEMBL541947 0.75 MEN1 (0.49) ALDH1A1KDM4EMEN1KMT2AGAA
SCHEMBL23677070 0.72 HDAC6 (0.40) MEN1KMT2AALOX5
SCHEMBL18890739 0.72 MEN1 (0.39) ALDH1A1KDM4EMEN1KMT2AGAA
SCHEMBL23677078 0.70 HDAC6 (0.47) MEN1KMT2AALOX5
SCHEMBL23677051 0.68 ALOX5 (0.48) KDM4EMEN1KMT2AGAAALOX5
SCHEMBL21880544 0.67 ALDH1A1 (0.37) ALDH1A1KDM4EMEN1KMT2AGAA
SCHEMBL22417632 0.67 GAA (0.46) ALDH1A1KDM4EMEN1KMT2AGAA
SCHEMBL2513769 0.67 ALOX5 (0.82) ALDH1A1KDM4EMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11299484-B2 Inhibiting fatty acid synthase (FASN) FORMA THERAPEUTICS, INC. (US) 2022-04-12 — — US disclosed
US-20210024508-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FORMA THERAPEUTICS, INC. 2021-01-28 — — US disclosed
US-20200115368-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FORMA THERAPEUTICS, INC. 2020-04-16 — — US disclosed
EP-3636637-A1 INHIBITING FATTY ACID SYNTHASE (FASN) Forma Therapeutics, Inc. (US) 2020-04-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024508-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FASN, SCD, FADS1 ALDH1A1 1168/4885KDM4E 3899/4885MEN1 4802/4885
US-20200115368-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FASN, SCD, FADS1 ALDH1A1 1168/4885KDM4E 3899/4885MEN1 4802/4885
US-11299484-B2 Inhibiting fatty acid synthase (FASN) FASN, SCD, FADS1 ALDH1A1 1168/4885KDM4E 3899/4885MEN1 4802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback